Damora Therapeutics, Inc.
DMRA
NASDAQ Capital Market32.99
USD
- -
- -
CIK
0001800315
ISIN
US36322Q2066
CUSIP
36322Q206
Return %
Stock
S&P500
1Y
816.39
19.01
3Y
-42.87
65.48
5Y
-70.61
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jennifer A. Jarrett
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 75 State Street Waltham MA United States of America 02109
- IPO Date
- Oct 29, 2020
- CIK
- 0001800315
- Website
- damoratx.com
- Similar Companies
- Business
- Galecto, Inc. is a clinical-stage biotechnology company focused on developing novel cancer and liver disease therapeutics, with a pipeline centered on galectin-3 modulators and related cancer signaling pathway inhibitors, including BRM-1420 in preclinical development. The company emphasizes small molecule candidates designed to modulate fibrosis and tumor biology, aiming for safe, efficacious treatments that support long-term use. Galecto is headquartered in Boston, MA, with global research and development activities and operations extending across North America and Europe. The firm was founded in 2009 and operates as a biotechnology innovator pursuing galectin biology–driven therapeutics for oncology and hepatology indications. Main products and services - Galectin-3 inhibitors: GB1211 series, including oral oral formulation for fibrosis-related liver disease and oncology combinations; mechanisms target galectin-3–mediated fibrotic and tumor pathways. - ENL-YEATS/FLT3 dual inhibitor program: BRM-1420, a preclinical dual inhibitor targeting ENL-YEATS and FLT3 for multiple AML genetic subsets; potential companion strategies with other anticancer agents. - Oncology combination therapies: GB1211 in conjunction with checkpoint inhibitors for various solid tumors; explores synergistic effects with immuno-oncology regimens. - Preclinical and discovery platforms: galectin modulators and ENL-YEATS/FLT3–targeted programs leveraged across translational research; in-house medicinal chemistry and biology capabilities to progress candidates toward IND enabling studies. - Strategic development and partnering services: collaboration with external sponsors for clinical development, regulatory planning, and translational studies; data generation to support future licensing or out-licensing opportunities. Latest major company changes - Strategic focus shift: completes a strategic alternatives review and narrows focus to oncology and liver disease programs, reinforcing core asset development and prioritization of lead pipelines; this shift consolidates capital and resources toward clinically advanced programs. - Global rights and pipeline expansion: secures global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for AML subsets, expanding the oncology portfolio and potential combination strategies. - Restructuring and funding updates: undertakes corporate restructuring to optimize organizational footprint and conserve cash; reports strategic review outcomes and runway estimates supported by existing cash balance to 2026, guiding ongoing trials and program valuation. - Corporate branding and market positioning: under consideration or execution of branding and ticker changes aligned with corporate identity; public disclosures indicate alignment with investor communications and market listing plans. Industry and segments - Industry: biotechnology, with a specialization in oncology and liver diseases. - Business segments: clinical-stage drug development; research and preclinical candidate generation; in-licensing and collaboration activities; potential future commercial operations contingent on regulatory approval. Geographic operations and subsidiaries - Operations span North America and Europe, with research sites and partnerships across Boston (USA) and European locations; multinational collaboration supports ongoing preclinical and translational studies. - Headquarters: Boston, MA, USA; significant presence in Europe for research and collaboration networks, including activities in the UK and continental Europe. Founding and corporate relationships - Founded in 2009; operates as an independent biotechnology company focused on galectin biology–driven therapeutics. - Notable relationships include partnerships with academic institutions and contract research organizations to advance preclinical programs and translational work; potential future licensing relationships anticipated as programs mature. Notes - Company name and branding: Galecto, Inc. has announced or is aligned with a potential rebranding pathway as it advances its oncology and liver disease programs; investors should verify current corporate naming and ticker status in the latest disclosures. The company’s core focus remains on developing galectin modulators and ENL-YEATS/FLT3–targeted therapies for cancer and liver diseases.
Damora Announces Redomestication from Delaware to Cayman Islands
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Recommendation of “Moderate Buy” by Analysts
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Analysts
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights